Payment overview · 2025
General Payments
$435.81
24 reported records · 14 companies
Healthcare provider profile · identity verified
Samara Epps Mcelroy, DO
Allopathic & Osteopathic Physicians|Family Medicine · SAINT PETERS, MO · NPI 1235431198
Verified facts
What the public records show
CMS Open Payments records show Samara Epps Mcelroy, DO received $435.81 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.27 | 13.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.19 | 13.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.63 | 12.8% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.97 | 9.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.88 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.72 | 6.8% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.81 | 6.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.75 | 6.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.07 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.53 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.49 | 4.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.99 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.05 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.46 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.81 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.63 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 669 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 127 |
| Lisinopril | Lisinopril | 449 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 88 |
| Losartan Potassium | Losartan Potassium | 307 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 63 |
| Omeprazole | Omeprazole | 223 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 60 |
| Metformin Hcl | Metformin Hcl | 193 | 58 |
| Gabapentin | Gabapentin | 177 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 49 |
| Furosemide | Furosemide | 167 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 52 |
| Metformin Hcl Er | Metformin Hcl | 131 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 36 |
| Alprazolam | Alprazolam | 124 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 30 |
| Trazodone Hcl | Trazodone Hcl | 111 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 29 |
| Simvastatin | Simvastatin | 107 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 30 |
| Bupropion Xl | Bupropion Hcl | 93 | 23 |
| Meloxicam | Meloxicam | 92 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Sertraline Hcl | Sertraline Hcl | 87 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 32 |
| Montelukast Sodium | Montelukast Sodium | 82 | 19 |
| Potassium Chloride | Potassium Chloride | 81 | 22 |
| Alendronate Sodium | Alendronate Sodium | 80 | 28 |
| Glimepiride | Glimepiride | 76 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 17 |
| Eliquis | Apixaban | 73 | 20 |
| Carvedilol | Carvedilol | 72 | 17 |
| Allopurinol | Allopurinol | 67 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 15 |
| Jardiance | Empagliflozin | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 17 |
| Atenolol | Atenolol | 56 | 17 |
| Fenofibrate | Fenofibrate | 55 | 14 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 14 |
| Ozempic | Semaglutide | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Buspirone Hcl | Buspirone Hcl | 48 | 14 |
| Lovastatin | Lovastatin | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 15 |
| Famotidine | Famotidine | 46 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Prednisone | Prednisone | 23 | 21 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Estradiol | Estradiol | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.81 · 24 records | Novo Nordisk Inc | AREXVY, Auvelity, Cologuard Collection Kit, ENTRESTO, EVENITY, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, INCEPTIV, KEVEYIS, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error